Tag: FDA Approved Treatments

Home / FDA Approved Treatments

Categories

Obecabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia

On November 8, 2024, the Food and Drug Administration sanctioned obecabtagene autoleucel (Aucatzyl, Autolus Inc.), a CD19-targeted genetically engineered autologous CAR T cell therapy, for people with...
fda-approved-treatments

Scan the code